Regina T. Herbst

Chemnitz, SN, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Eltrombopag plus cyclosporine A for moderate aplastic anemia (EMAA): a placebo-controlled, double-blind, phase 3 trial.

Eltrombopag plus cyclosporine A for moderate aplastic anemia (EMAA): a placebo-controlled, double-blind, phase 3 trial.

Journal: Blood

Published: January 23, 2026

Case Report: Leptomeningeal involvement in chronic lymphocytic leukemia patients with central nervous system infection: extramedullary manifestation or transmigration of leukocytes-how to treat this type of CLL?

Case Report: Leptomeningeal involvement in chronic lymphocytic leukemia patients with central nervous system infection: extramedullary manifestation or transmigration of leukocytes-how to treat this type of CLL?

Journal: Frontiers in oncology

Published: January 15, 2026

Inhibition of high CXCR4 with Motixafortide and absence of single-cell MRD predict outcome after AML consolidation.

Inhibition of high CXCR4 with Motixafortide and absence of single-cell MRD predict outcome after AML consolidation.

Journal: Blood

Published: October 14, 2025

Inhibition of high CXCR4 with motixafortide and absence of single-cell MRD predict outcome after AML consolidation.

Inhibition of high CXCR4 with motixafortide and absence of single-cell MRD predict outcome after AML consolidation.

Journal: Blood

Published: October 14, 2025

Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction Therapy.

Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction Therapy.

Journal: American journal of hematology

Published: August 18, 2025

Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial.

Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial.

Journal: Blood

Published: July 21, 2025

Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial.

Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial.

Journal: Blood

Published: July 21, 2025

Hypomethylating Therapy With or Without Eltrombopag in Elderly Patients With Acute Myeloid Leukemia: Results From the Randomized, Placebo-Controlled Phase 2 DELTA Trial.

Hypomethylating Therapy With or Without Eltrombopag in Elderly Patients With Acute Myeloid Leukemia: Results From the Randomized, Placebo-Controlled Phase 2 DELTA Trial.

Journal: American journal of hematology

Published: June 25, 2025

Induction chemotherapy with CPX-351 in acute myeloid leukemia: revisiting the role of early bone marrow assessment.

Induction chemotherapy with CPX-351 in acute myeloid leukemia: revisiting the role of early bone marrow assessment.

Journal: Leukemia

Published: February 20, 2025

Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia.

Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 16, 2024

Is there still a place for autologous salvage transplantation in relapsed/refractory multiple myeloma in the era of novel therapies?

Is there still a place for autologous salvage transplantation in relapsed/refractory multiple myeloma in the era of novel therapies?

Journal: Annals of hematology

Published: June 07, 2024

Challenges in the treatment of soft-tissue plasmacytoma: a retrospective analysis of 120 patients with extramedullary multiple myeloma.

Challenges in the treatment of soft-tissue plasmacytoma: a retrospective analysis of 120 patients with extramedullary multiple myeloma.

Journal: Journal of cancer research and clinical oncology

Published: May 15, 2024

Showing 1-12 of 31

Last Updated: 09/26/2026